There are some potential therapeutic targets in PCa, including AR, c-Myc, AKT, and recombinant forkhead box protein A1 (FOXA1) [21–24], among which AR has attracted considerable research attention, but the role of c-Myc oncoprotein in PCa remains little studied. Here, FOXA1 is linked to posterior cortical atrophy.